Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine (NASDAQ:IRON), a clinical-stage biopharmaceutical company specializing in treatments for hematologic diseases, has announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference on Tuesday, November 19th at 8:35 a.m. ET, and the Jefferies London Healthcare Conference on Thursday, November 21st at 9:30 a.m. GMT. Live webcasts will be accessible through the company's investor relations website, with archived replays available post-events.
Disc Medicine (NASDAQ:IRON), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento delle malattie ematologiche, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda presenterà alla Stifel 2024 Healthcare Conference martedì 19 novembre alle 8:35 a.m. ET e alla Jefferies London Healthcare Conference giovedì 21 novembre alle 9:30 a.m. GMT. Le dirette streaming saranno accessibili tramite il sito web delle relazioni con gli investitori dell'azienda, con registrazioni disponibili dopo gli eventi.
Disc Medicine (NASDAQ:IRON), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades hematológicas, ha anunciado su participación en dos próximas conferencias para inversores. La empresa se presentará en la Stifel 2024 Healthcare Conference el martes 19 de noviembre a las 8:35 a.m. ET y en la Jefferies London Healthcare Conference el jueves 21 de noviembre a las 9:30 a.m. GMT. Las transmisiones en vivo estarán disponibles a través del sitio web de relaciones con inversores de la empresa, con repeticiones archivadas disponibles después de los eventos.
Disc Medicine (NASDAQ:IRON)은 혈액 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사로, 두 개의 다가오는 투자자 회의에 대한 참여를 발표했습니다. 회사는 11월 19일 화요일 오전 8시 35분 ET에 Stifel 2024 Healthcare Conference에서 발표할 예정이며, 11월 21일 목요일 오전 9시 30분 GMT에 Jefferies London Healthcare Conference에서 발표할 예정입니다. 실시간 웹캐스트는 회사의 투자자 관계 웹사이트를 통해 접속 가능하며, 이벤트 후에는 아카이브된 재생이 제공됩니다.
Disc Medicine (NASDAQ:IRON), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements des maladies hématologiques, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise présentera à la Stifel 2024 Healthcare Conference le mardi 19 novembre à 8h35 ET, et à la Jefferies London Healthcare Conference le jeudi 21 novembre à 9h30 GMT. Des webcasts en direct seront accessibles via le site web des relations investisseurs de l'entreprise, avec des rediffusions archivées disponibles après les événements.
Disc Medicine (NASDAQ:IRON), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung hämatologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird am Dienstag, dem 19. November, um 8:35 Uhr ET auf der Stifel 2024 Healthcare Conference und am Donnerstag, dem 21. November, um 9:30 Uhr GMT auf der Jefferies London Healthcare Conference präsentieren. Live-Webcasts werden über die Investor Relations-Website des Unternehmens zugänglich sein, mit archivierten Wiederholungen, die nach den Veranstaltungen verfügbar sind.
- None.
- None.
WATERTOWN, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will present at two upcoming investor conferences:
- Stifel 2024 Healthcare Conference on Tuesday, November 19th at 8:35 a.m. ET.
- Jefferies London Healthcare Conference on Thursday, November 21st at 9:30 a.m. GMT.
A live webcast of the presentations will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
When will Disc Medicine (IRON) present at the Stifel 2024 Healthcare Conference?
What time is Disc Medicine's (IRON) presentation at the Jefferies London Healthcare Conference?
How can investors watch Disc Medicine's (IRON) conference presentations?
Which investor conferences is Disc Medicine (IRON) attending in November 2024?
